A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Actinium-225
antibodies
cancer treatment
radiolabeled peptides
radiopharmaceuticals
targeted alpha therapy (TAT)
Journal
Chemical biology & drug design
ISSN: 1747-0285
Titre abrégé: Chem Biol Drug Des
Pays: England
ID NLM: 101262549
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
03
06
2023
received:
16
03
2022
accepted:
17
07
2023
medline:
23
10
2023
pubmed:
16
9
2023
entrez:
16
9
2023
Statut:
ppublish
Résumé
In nuclear medicine, cancers that cannot be cured or can only be treated partially by traditional techniques like surgery or chemotherapy are killed by ionizing radiation as a form of therapeutic treatment. Actinium-225 is an alpha-emitting radionuclide that is highly encouraging as a therapeutic approach and more promising for targeted alpha therapy (TAT). Actinium-225 is the best candidate for tumor cells treatment and has physical characteristics such as high (LET) linear energy transfer (150 keV per μm), half-life (t
Substances chimiques
Actinium
NIK1K0956U
Actinium-225
0
Radioisotopes
0
Radiopharmaceuticals
0
(225)Ac-PSMA-617
0
Edotreotide
U194AS08HZ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1276-1292Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Abbasi, A., Dadashpour, M., & Alipourfard, I. (2021). Calculation of radium-223 and actinium-225 α-emitter radiopharmaceuticals dose rates in treatment of metastatic castration-resistant prostate cancer. Journal of Cancer Research and Therapeutics, 17, 348-352.
Agrawal, S. (2020). The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning. Indian Journal of Urology: IJU: Journal of the Urological Society of India, 36, 69-70.
Allen, B. J., Singla, A. A., Rizvi, S. M. A., Graham, P., Bruchertseifer, F., Apostolidis, C., & Morgenstern, A. (2011). Analysis of patient survival in a phase I trial of systemic targeted α-therapy for metastatic melanoma. Immunotherapy, 3, 1041-1050.
Ametamey, S. M., Honer, M., & Schubiger, P. A. (2008). Molecular imaging with PET. Chemical Reviews, 108, 1501-1516.
Artun, O. (2017). Estimation of the production of medical Ac-225 on thorium material via proton accelerator. Applied Radiation and Isotopes, 127, 166-172.
Ballal, S., Yadav, M. P., Bal, C., Sahoo, R. K., & Tripathi, M. (2020). Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: First clinical experience on the efficacy and safety. European Journal of Nuclear Medicine and Molecular Imaging, 47, 934-946.
Ballangrud, Å. M., Yang, W.-H., Palm, S., Enmon, R., Borchardt, P. E., Pellegrini, V. A., McDevitt, M. R., Scheinberg, D. A., & Sgouros, G. (2004). Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (Herceptin) targeting of breast cancer spheroids. Clinical Cancer Research, 10, 4489-4497.
Bell, M. M., Gutsche, N. T., King, A. P., Baidoo, K. E., Kelada, O. J., Choyke, P. L., & Escorcia, F. E. (2021). Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma. Molecules, 26, 4.
Bicak, M., Lückerath, K., Kalidindi, T., Phelps, M. E., Strand, S.-E., Morris, M. J., Radu, C. G., Damoiseaux, R., Peltola, M. T., & Peekhaus, N. (2020). Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proceedings of the National Academy of Sciences, 117, 15172-15181.
Bloch, E. M., Hull, J., Green-Thompson, R., Ingram, C., Crookes, R. L., Fawcus, S., Anthony, J., Courtney, L., Roubinian, N., & Jauregui, A. (2020). Antenatal blood transfusion in South Africa: Indications and practice in a high-HIV-prevalence setting. Transfusion, 60, 479-487.
Bodei, L., Schöder, H., Baum, R. P., Herrmann, K., Strosberg, J., Caplin, M., Öberg, K., & Modlin, I. M. (2020). Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. The Lancet Oncology, 21, e431-e443.
Boll, R. A., Malkemus, D., & Mirzadeh, S. (2005). Production of actinium-225 for alpha particle mediated radioimmunotherapy. Applied Radiation and Isotopes, 62, 667-679.
Boros, E., & Holland, J. P. (2018). Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. Journal of Labelled Compounds and Radiopharmaceuticals, 61, 652-671.
Brechbiel, M. W. (2007). Targeted α-therapy: Past, present, future? Dalton Transactions, 43, 4918-4928.
Carrasquillo, J. A., O'Donoghue, J. A., Beylergil, V., Ruan, S., Pandit-Taskar, N., Larson, S. M., Smith-Jones, P. M., Lyashchenko, S. K., Ohishi, N., & Ohtomo, T. (2018). I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Research, 8, 1-11.
Chappell, L. L., Deal, K. A., Dadachova, E., & Brechbiel, M. W. (2000). Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for225Ac radioimmunotherapy applications. Bioconjugate Chemistry, 11, 510-519.
Chatterjee, S., Czerwinski, K. R., Fitzgerald, H. A., Lakes, A. L., Liao, Z., Ludwig, R. C., McBride, K. M., & Vlasenko, V. P. (2023). Delivery of radiopharmaceuticals and theranostic agents: Targeted alpha therapy. In Novel Platforms for Drug Delivery Applications (pp. 349-404). Elsevier.
Cheal, S., McDevitt, M., Patel, M., Yang, G., Pillarsetty, N., Xu, H., Guo, H.-F., Fung, E., Cheung, N.-K., & Ouerfelli, O. (2018). Pretargeted radioimmunotherapy with 225Ac-proteus-DOTA hapten. Society of Nuclear Medicine, 59(1), 123-123.
Cheal, S. M., McDevitt, M. R., Santich, B. H., Patel, M., Yang, G., Fung, E. K., Veach, D. R., Bell, M., Ahad, A., & Vargas, D. B. (2020). Alpha radioimmunotherapy using225Ac-proteus-DOTA for solid tumors-safety at curative doses. Theranostics, 10, 11359-11375.
Chege, B. W., Tkhorik, O., Waheed, M. F., Pavlov, A., Kahraman, M. C., James, I. U., Haroon, J., Komakech, I., Zaharov, I., & Radchenko, V. (2019). A study of current and potential suppliers of actinium-225 for targeted alpha therapy. Netw. Innovations Nuclear Applied, 4, 4-12.
Cortez, A., Josefsson, A., McCarty, G., Shtekler, A. E., Rao, A., Austin, Z., & Nedrow, J. R. (2020). Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma. Nuclear Medicine and Biology, 88, 62-72.
Couturier, O., Supiot, S., Degraef-Mougin, M., Faivre-Chauvet, A., Carlier, T., Chatal, J.-F., Davodeau, F., & Cherel, M. (2005). Cancer radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine and Molecular Imaging, 32, 601-614.
Cucchi, D. G., Polak, T. B., Ossenkoppele, G. J., Groot, U. D., Carin, A., Cloos, J., Zweegman, S., & Janssen, J. J. (2021). Two decades of targeted therapies in acute myeloid leukemia. Leukemia, 35, 651-660.
Davis, I., Glowienka, K., Boll, R., Deal, K., Brechbiel, M., Stabin, M., Bochsler, P., Mirzadeh, S., & Kennel, S. (1999). Comparison of 225actinium chelates: Tissue distribution and radiotoxicity. Nuclear Medicine and Biology, 26, 581-589.
Dawicki, W., Allen, K. J., Jiao, R., Malo, M. E., Helal, M., Berger, M. S., Ludwig, D. L., & Dadachova, E. (2019). Daratumumab-225Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors. Oncoimmunology, 8, 1607673.
de Kruijff, R., Raavé, R., Kip, A., Molkenboer-Kuenen, J., Morgenstern, A., Bruchertseifer, F., Heskamp, S., & Denkova, A. (2019a). Therapeutic efficacy of 225Ac-containing Polymersomes. Journal of Medical Imaging and Radiation Sciences, 50, S7.
De Kruijff, R., Raavé, R., Kip, A., Molkenboer-Kuenen, J., Morgenstern, A., Bruchertseifer, F., Heskamp, S., & Denkova, A. (2019b). The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier. Scientific Reports, 9, 1-13.
De Kruijff, R., Van der Meer, A., Windmeijer, C., Kouwenberg, J., Morgenstern, A., Bruchertseifer, F., Sminia, P., & Denkova, A. (2018). The therapeutic potential of polymersomes loaded with 225Ac evaluated in 2D and 3D in vitro glioma models. European Journal of Pharmaceutics and Biopharmaceutics, 127, 85-91.
De Vincentis, G., Gerritsen, W., Gschwend, J., Hacker, M., Lewington, V., O'Sullivan, J., Oya, M., Pacilio, M., Parker, C., & Shore, N. (2019). Advances in targeted alpha therapy for prostate cancer. Annals of Oncology, 30, 1728-1739.
Desai, P., Rimal, R., Sahnoun, S. E., Mottaghy, F. M., Möller, M., Morgenroth, A., & Singh, S. (2022). Radiolabeled nanocarriers as Theranostics-Advancement from peptides to nanocarriers. Small, 18, 2200673.
Dhiman, D., Vatsa, R., & Sood, A. (2022). Challenges and opportunities in developing Actinium-225 radiopharmaceuticals. Nuclear Medicine Communications, 43(9), 970-977. https://doi.org/10.1097/MNM.0000000000001594
Dumond, A. R., Rodnick, M. E., Piert, M. R., & Scott, P. J. H. (2022). Synthesis of (225)Ac-PSMA-617 for preclinical use. Current Radiopharmaceuticals, 15, 96-103.
Engle, J. W. (2018). The production of Ac-225. Current Radiopharmaceuticals, 11, 173-179.
Essler, M., Gärtner, F., Neff, F., Blechert, B., Senekowitsch-Schmidtke, R., Bruchertseifer, F., Morgenstern, A., & Seidl, C. (2012). Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. European Journal of Nuclear Medicine & Molecular Imaging, 39, 602-612.
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J.-F. (2021). Overview of the Most promising radionuclides for targeted alpha therapy: The “hopeful eight”. Pharmaceutics, 13, 906.
Feijtel, D., de Jong, M., & Nonnekens, J. (2020). Peptide receptor radionuclide therapy: Looking Back, looking forward. Current Topics in Medicinal Chemistry, 20, 2959-2969.
Fitzsimmons, J., & Atcher, R. (2007). Synthesis and evaluation of a water-soluble polymer to reduce Ac-225 daughter migration. Journal of Labelled Compounds and Radiopharmaceuticals, 50, 147-153.
Foss, C. A., Mease, R. C., Fan, H., Wang, Y., Ravert, H. T., Dannals, R. F., Olszewski, R. T., Heston, W. D., Kozikowski, A. P., & Pomper, M. G. (2005). Radiolabeled small-molecule ligands for prostate-specific membrane antigen:In vivoImaging in experimental models of prostate cancer. Clinical Cancer Research, 11, 4022-4028.
Frantellizzi, V., Ricci, M., Cimini, A., Filippi, L., Conte, M., De Feo, M. S., & De Vincentis, G. (2023). The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? Applied Sciences, 13, 1890.
Gao, Y., Chen, L., Ge, J., Cui, J., Zeng, J., & Gao, M. (2021). A Pretargeting strategy enabled by bioorthogonal reactions towards advanced nuclear medicines: Application and perspective. Chemical Research in Chinese Universities, 37, 870-879.
Gao, Y., Grover, P., & Schreckenbach, G. (2021). Stabilization of hydrated AcIIIcation: The role of superatom states in actinium-water bonding. Chemical Science, 12, 2655-2666.
Garashchenko, B., Korsakova, V., & Yakovlev, R. Y. (2018). Radiopharmaceuticals based on alpha emitters: Preparation, properties, and application. Physics of Atomic Nuclei, 81, 1515-1525.
Garg, R., Allen, K. J., Dawicki, W., Geoghegan, E. M., Ludwig, D. L., & Dadachova, E. (2021). 225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models. Cancer Medicine, 10, 1128-1140.
Giné, E., Gutiérrez-García, G., & López-Guillermo, A. (2010). Current immunochemotherapy strategies in follicular lymphoma. Advances in Therapy, 27, 704-713.
Govindan, S. V., Griffiths, G. L., Hansen, H. J., Horak, I. D., & Goldenberg, D. M. (2005). Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technology in Cancer Research & Treatment, 4, 375-391.
Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., & Schreckenberger, M. (2014). DNA double Strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy. PLoS One, 9, e88239.
Graves, S. A., & Hobbs, R. F. (2021). Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Seminars in Radiation Oncology, 31, 37-44.
Grossrubatscher, E., Fanciulli, G., Pes, L., Sesti, F., Dolci, C., de Cicco, F., Colao, A., Faggiano, A., & N. Group. (2020). Advances in the Management of Medullary Thyroid Carcinoma: Focus on peptide receptor radionuclide therapy. Journal of Clinical Medicine, 9, 3507.
Guerra Liberal, F. D., O'Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020). Targeted alpha therapy: Current clinical applications. Cancer Biotherapy & Radiopharmaceuticals, 35, 404-417.
Hanssens, H. (2018). Generation and Validation of Nanobodies Targeting Brain Tumors with Aberrant Expression of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2. https://www.scriptiebank.be/scriptie/2018/generation-and-validation-nanobodies-targeting-brain-tumors-aberrant-expression
Harvey, J. T. (2018). NorthStar perspectives for Actinium-225 production at commercial scale. Current Radiopharmaceuticals, 11, 180-191.
Hatcher-Lamarre, J. L., Sanders, V. A., Rahman, M., Cutler, C. S., & Francesconi, L. C. (2021). Alpha emitting nuclides for targeted therapy. Nuclear Medicine and Biology, 92, 228-240.
Hooijman, E. L., Chalashkan, Y., Ling, S. W., Kahyargil, F. F., Segbers, M., Bruchertseifer, F., Morgenstern, A., Seimbille, Y., Koolen, S. L., & Brabander, T. (2021). Development of [225Ac]Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC. Pharmaceutics, 13, 715.
Hope, T., Mehr, S., Morris, M., Li, D., Halperin, M. D., Strosberg, J., Soares, H., Jacene, H., Pavel, M., & Ferreira, D. (2023). Proc. Endocrine Abstracts. Bioscientifica 89.
Iikuni, S., Tarumizu, Y., Nakashima, K., Higaki, Y., Ichikawa, H., Watanabe, H., & Ono, M. (2021). Radiotheranostics using a Novel225Ac-labeled radioligand with improved pharmacokinetics targeting prostate-specific membrane antigen. Journal of Medicinal Chemistry, 64, 13429-13438.
Ilhan, H., Gosewisch, A., Böning, G., Völter, F., Zacherl, M., Unterrainer, M., Bartenstein, P., Todica, A., & Gildehaus, F. J. (2021). Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC. European Journal of Nuclear Medicine and Molecular Imaging, 48, 1262-1263.
Imam, S. K. (2001). Advancements in cancer therapy with alpha-Emitters: A review. International Journal of Radiation Oncology* Biology* Physics, 51, 271-278.
Johnson, J. D., Heines, M., Bruchertseifer, F., Chevallay, E., Cocolios, T. E., Dockx, K., Duchemin, C., Heinitz, S., Heinke, R., & Hurier, S. (2023). Resonant laser ionization and mass separation of 225Ac. Scientific Reports, 13, 1347.
Jurcic, J. G., Ravandi, F., Pagel, J. M., Park, J. H., Smith, B. D., Douer, D., Levy, M. Y., Estey, E., Kantarjian, H. M., & Earle, D. (2015). Phase I trial of alpha-particle therapy with Actinium-225(225Ac)-lintuzumab(anti-CD33) and low-dose cytrarabine (LDAC) in older patients with untreated actue myeloid leukemia (AML). American society of clinical oncology, 33(15), 7050.
Jurcic, J. G., & Rosenblat, T. L. (2014). Targeted alpha-particle immunotherapy for acute myeloid leukemia. American Society of Clinical Oncology Educational Book, 34, e126-e131.
Kadassery, K. J., King, A. P., Fayn, S., Baidoo, K. E., MacMillan, S. N., Escorcia, F. E., & Wilson, J. J. (2022). H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. Bioconjugate Chemistry, 33(6), 1222-1231.
Kang, C. S., Lee, K. C., & Lee, Y. J. (2019). Targeted alpha therapy for cancer using metallic radioisotopes. Journal of Radiopharmaceuticals and Molecular Probes, 5, 135-144.
Kannengießer, S. (2013). Optimization of the Synthesis of Ac-225-labelled DOTA-Radioimmunoconjugates for Targeted Alpha Therapy. Doctoral dissertation. Based on Investigations on the Complexation of Trivalent Actinides by DOTA https://doi.org/10.11588/heidok.00015207
Kassis, A. I., & Adelstein, S. J. (2005). Radiobiologic principles in radionuclide therapy. Journal of Nuclear Medicine, 46, 4S-12S.
Kelly, J. M., Amor-Coarasa, A., Nikolopoulou, A., Kim, D., Williams, C., Jr., Vallabhajosula, S., & Babich, J. W. (2017). Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68 Ga 3+, 111 In 3+, 177 Lu 3+ and 225 Ac 3+. Nuclear Medicine and Biology, 55, 38-46.
Kelly, J. M., Amor-Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C., Thiele, N. A., Schlyer, D., Wilson, J. J., DiMagno, S. G., & Babich, J. W. (2019). A single dose of225Ac-RPS-074 induces a complete tumor response in an LNCaP xenograft model. Journal of Nuclear Medicine, 60, 649-655.
Kelly, J. M., Amor-Coarasa, A., Ponnala, S., Nikolopoulou, A., Williams, C., Jr., Thiele, N. A., Schlyer, D., Wilson, J. J., DiMagno, S. G., & Babich, J. W. (2019). Journal of nuclear medicine: Official publication, society of. Nuclear Medicine, 60, 649-655.
Kelly, J. M., Amor-Coarasa, A., Sweeney, E., Wilson, J. J., Causey, P. W., & Babich, J. (2021a). A suitable timepoint for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 6, 1-14.
Kelly, J. M., Amor-Coarasa, A., Sweeney, E., Wilson, J. J., Causey, P. W., & Babich, J. W. (2021b). A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals. EJNMMI Radiopharmacy and Chemistry, 6, 1-14.
Kelly, V. J., Wu, S.-T., Gottumukkala, V., Coelho, R., Palmer, K., Nair, S., Erick, T., Puri, R., Ilovich, O., & Mukherjee, P. (2020). Preclinical evaluation of an111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer. Theranostics, 10, 6946-6958.
Kennel, S. J., Brechbiel, M. W., Milenic, D. E., Schlom, J., & Mirzadeh, S. (2002). Actinium-225 conjugates of MAb CC49 and humanized ΔCH2CC49. Cancer Biotherapy and Radiopharmaceuticals, 17, 219-231.
Kennel, S. J., Chappell, L. L., Dadachova, K., Brechbiel, M. W., Lankford, T. K., Davis, I. A., Stabin, M., & Mirzadeh, S. (2000). Evaluation of225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biotherapy and Radiopharmaceuticals, 15, 235-244.
Kim, Y.-S., & Brechbiel, M. W. (2012). An overview of targeted alpha therapy. Tumor Biology, 33, 573-590.
Knapp, F. F. (2016). Radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine. Radiopharmaceuticals for therapy, 3-23.
Kratochwil, C., Haberkorn, U., & Giesel, F. L. (2020). 225Ac-PSMA-617 for therapy of prostate cancer. Proceeding Seminars in Nuclear Medicine, 133-140.
Lakes, A. L., An, D. D., Gauny, S. S., Ansoborlo, C., Liang, B. H., Rees, J. A., McKnight, K. D., Karsunky, H., & Abergel, R. J. (2020). Evaluating225Ac and177Lu radioimmunoconjugates against antibody-drug conjugates for small-cell lung cancer. Molecular Pharmaceutics, 17, 4270-4279.
Lau, J., Jacobson, O., Niu, G., Lin, K.-S., Bénard, F., & Chen, X. (2019). Bench to bedside: Albumin binders for improved cancer radioligand therapies. Bioconjugate Chemistry, 30, 487-502.
Lemaître, T. A., Burgoyne, A. R., Ooms, M., Parac-Vogt, T. N., & Cardinaels, T. (2022). Inorganic radiolabeled nanomaterials in cancer therapy: A review. ACS Applied Nano Materials, 5, 8680-8709.
Li, D., Minnix, M., Allen, R., Bading, J., Chea, J., Wong, P., Bowles, N., Poku, E., & Shively, J. E. (2021). Preclinical PET imaging of NTSR-1-positive tumors with64Cu- and68Ga-DOTA-neurotensin analogs and therapy with an225Ac-DOTA-neurotensin analog. Cancer Biotherapy & Radiopharmaceuticals, 36, 651-661.
Li, L., Rousseau, J., Jaraquemada-Pelaez, M. D. G., Wang, X., Robertson, A., Radchenko, V., Schaffer, P., Lin, K.-S., Bénard, F., & Orvig, C. (2020). 225Ac-H4py4pa for targeted alpha therapy. Bioconjugate Chemistry, 32, 1348-1363.
Li, Y., Chyan, M.-K., Hamlin, D. K., Nguyen, H., Vessella, R., & Wilbur, D. S. (2021). Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. Nuclear Medicine and Biology, 92, 217-227.
Maguire, W. F., McDevitt, M. R., Smith-Jones, P. M., & Scheinberg, D. A. (2014). Journal of nuclear medicine: Official publication. Society of Nuclear Medicine, 55, 1492-1498.
Majkowska-Pilip, A., Rius, M., Bruchertseifer, F., Apostolidis, C., Weis, M., Bonelli, M., Laurenza, M., Królicki, L., & Morgenstern, A. (2018). In vitro evaluation of225Ac-DOTA-substance P for targeted alpha therapy of glioblastoma multiforme. Chemical Biology & Drug Design, 92, 1344-1356.
Matson, M. L., Villa, C. H., Ananta, J. S., Law, J. J., Scheinberg, D. A., & Wilson, L. J. (2015). Encapsulation of α-particle-Emitting225Ac3+ions within carbon nanotubes. Journal of Nuclear Medicine, 56, 897-900.
McDevitt, M., Ma, D., Simon, J., Frank, K., & Scheinberg, D. (2003). Applied radiation and isotopes: Including data, instrumentation and methods for use in agriculture. Industry and Medicine, 57, 841-847.
McDevitt, M. R., Ma, D., Simon, J., Frank, R. K., & Scheinberg, D. A. (2002). Design and synthesis of 225Ac radioimmunopharmaceuticals. Applied Radiation and Isotopes, 57, 841-847.
McDevitt, M. R., Sgouros, G., Finn, R. D., Humm, J. L., Jurcic, J. G., Larson, S. M., & Scheinberg, D. A. (1998). Radioimmunotherapy with alpha-emitting nuclides. European Journal of Nuclear Medicine, 25, 1341-1351.
McDevitt, M. R., Thorek, D. L., Hashimoto, T., Gondo, T., Veach, D. R., Sharma, S. K., Kalidindi, T. M., Abou, D. S., Watson, P. A., & Beattie, B. J. (2018). Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nature Communications, 9, 1-11.
Merkx, R., Kip, A., Franssen, G., Oosterwijk, E., Morgenstern, A., Bruchertseifer, F., Wheatcroft, M., Yan, E., Rijpkema, M., & Heskamp, S. (2020). Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model. European Urology Open Science, 19, e1482.
Miederer, M., Scheinberg, D. A., & McDevitt, M. R. (2008). Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews, 60, 1371-1382.
Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020). Supply and clinical application of actinium-225 and bismuth-213. Proceedings Seminars in Nuclear Medicine, 50(2), 119-123.
Motaleb, M. A., & Nassar, M. Y. (2014). Preparation, molecular modeling and biodistribution of 99mTc-phytochlorin complex. Journal of Radioanalytical and Nuclear Chemistry, 299, 1759-1766.
Mulford, D. A., Scheinberg, D. A., & Jurcic, J. G. (2005). The promise of targeted {alpha}-particle therapy. Journal of Nuclear Medicine, 46, 199S-204S.
Nedrow, J. R., Josefsson, A., Park, S., Bäck, T., Hobbs, R. F., Brayton, C., Bruchertseifer, F., Morgenstern, A., & Sgouros, G. (2017). Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model. EJNMMI Research, 7, 1-16.
Nelson, B. J., Andersson, J. D., & Wuest, F. (2021). Targeted alpha therapy: Progress in radionuclide production, radiochemistry, and applications. Pharmaceutics, 13, 49.
Norenberg, J., Daniels, T., Kevin, J., Heloisa, S., Kusewitt, D., Hesterman, J., Orcutt, K., Nysus, M., Goff, C., & Jacquez, Q. (2019). Pre-clinical evaluation of 225Ac-DOTATOC pharmacokinetics, dosimetry, and istopathology to enable Phase-1 clinical trial in patients with neuroendocrine tumors. Journal of Medical Imaging and Radiation Sciences, 50, S105.
Ocak, M., Toklu, T., Demirci, E., Selçuk, N., & Kabasakal, L. (2020). Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. European Journal of Nuclear Medicine and Molecular Imaging, 47, 2711-2712.
Older, R. A., Synder, B., Krupski, T. L., Glembocki, D. J., & Gillenwater, J. Y. (2001). Radioactive implant migration IN patients treated for localized prostate cancer with interstitial BRACHYTHERAPY. The Journal of Urology, 165, 1590-1592.
Pallares, R. M., Flick, M., Shield, K. M., Bailey, T. A., Velappan, N., Lillo, A. M., & Abergel, R. (2022). Developments of an actinium-225 radioimmunoconjugate for targeted alpha therapy against SARS-CoV-2. New Journal of Chemistry, 46(33), 15795-15798.
Pandya, D., Batista, I., Zhu, D., Mintz, A., & Wadas, T. (2014). Radiochemistry and biological evluation of 225Ac-DOTA-c (RGDyK), a potential radiopharmaceutical for targeted alpha particle therapy. Society of Nuclear Medicine, 55(1), 1477.
Pandya, D. N., Hantgan, R., Budzevich, M. M., Kock, N. D., Morse, D. L., Batista, I., Mintz, A., Li, K. C., & Wadas, T. J. (2016). Preliminary therapy evaluation of225Ac-DOTA-c(RGDyK) demonstrates that Cerenkov radiation derived from225Ac daughter decay can Be detected by optical imaging forIn VivoTumor visualization. Theranostics, 6, 698-709.
Parihar, A. S., Chandekar, K. R., Singh, H., Sood, A., & Mittal, B. R. (2021). Orbital and brain metastases on 68 Ga PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy. Asia Oceania Journal of Nuclear Medicine and Biology, 9, 67.
Perron, R., Gendron, D., & Causey, P. W. (2020). Construction of a thorium/actinium generator at the Canadian nuclear laboratories. Applied Radiation and Isotopes, 164, 109262.
Pfannkuchen, N., Bausbacher, N., Pektor, S., Miederer, M., & Rosch, F. (2018). In vivoEvaluation of [225Ac]Ac-DOTAZOLfor α-therapy of bone metastases. Current Radiopharmaceuticals, 11, 223-230.
Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2019). Leveraging bioorthogonal click chemistry to improve 225Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clinical Cancer Research, 25, 868-880.
Poty, S., Membreno, R., Glaser, J., Ragupathi, A., Scholz, W., Zeglis, B., & Lewis, J. (2018). The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of225Ac-labelled radioimmunoconjugates. Chemical Communications, 54, 2599-2602.
Price, E. W., & Orvig, C. (2014). Matching chelators to radiometals for radiopharmaceuticals. Chemical Society Reviews, 43, 260-290.
Pruszynski, M., D'Huyvetter, M., Bruchertseifer, F., Morgenstern, A., & Lahoutte, T. (2018). Evaluation of an anti-HER2 nanobody labeled with225Ac for targeted α-particle therapy of cancer. Molecular Pharmaceutics, 15, 1457-1466.
Qin, Y., Imobersteg, S., Blanc, A., Frank, S., Schibli, R., Béhé, M. P., & Grzmil, M. (2020). Evaluation of Actinium-225 labeled Minigastrin analogue [225Ac]Ac-DOTA-PP-F11N for targeted alpha particle therapy. Pharmaceutics, 12, 1088.
Ramogida, C. F., & Orvig, C. (2013). Tumour targeting with radiometals for diagnosis and therapy. Chemical Communications, 49, 4720-4739.
Ramogida, C. F., Robertson, A. K., Jermilova, U., Zhang, C., Yang, H., Kunz, P., Lassen, J., Bratanovic, I., Brown, V., & Southcott, L. (2019). Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac. EJNMMI Radiopharmacy and Chemistry, 4, 1-20.
Rathke, H., Kratochwil, C., Hohenberger, R., Giesel, F. L., Bruchertseifer, F., Flechsig, P., Morgenstern, A., Hein, M., Plinkert, P., & Haberkorn, U. (2019). Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. European Journal of Nuclear Medicine and Molecular Imaging, 46, 139-147.
Reissig, F., Bauer, D., Zarschler, K., Novy, Z., Bendova, K., Ludik, M.-C., Kopka, K., Pietzsch, H.-J., Petrik, M., & Mamat, C. (2021). Towards targeted alpha therapy with actinium-225: Chelators for mild condition radiolabeling and targeting PSMA-a proof of concept study. Cancers, 13, 1974.
Robertson, A. K., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018). Development of225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Current Radiopharmaceuticals, 11, 156-172.
Salvanou, E.-A., Stellas, D., Tsoukalas, C., Mavroidi, B., Paravatou-Petsotas, M., Kalogeropoulos, N., Xanthopoulos, S., Denat, F., Laurent, G., Bazzi, R., Roux, S., & Bouziotis, P. (2020). A proof-of-concept study on the therapeutic potential of Au nanoparticles radiolabeled with the alpha-emitter Actinium-225. Pharmaceutics, 12, 188.
Sarko, D., Eisenhut, M., Haberkorn, U., & Mier, W. (2012). Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases. Current Medicinal Chemistry, 19, 2667-2688.
Satapathy, S., Sood, A., Das, C. K., & Mittal, B. R. (2021). Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer-a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 24(3), 880-890.
Sattiraju, A., Sai, K. K. S., Xuan, A., Pandya, D. N., Almaguel, F. G., Wadas, T. J., Herpai, D. M., Debinski, W., & Mintz, A. (2017). IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget, 8, 42997-43007.
Scheinberg, D. A., & McDevitt, M. R. (2011). Actinium-225 in targeted alpha-particle therapeutic applications. Current Radiopharmaceuticals, 4, 306-320.
Seniwal, B., Thipe, V. C., Singh, S., Fonseca, T. C., & Freitas, L. F. D. (2022). Recent advances in brachytherapy using radioactive nanoparticles. Frontiers in Oncology, 11, 1-24.
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010). MIRD pamphlet No. 22 (abridged): Radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. Journal of Nuclear Medicine, 51, 311-328.
Shahi, A., Weiss, G. E., Bhattacharya, S., Baiu, D. C., Marino, R., Pula, T., Callander, N. S., Asimakopoulos, F., & Otto, M. (2021). Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical. Leukemia & Lymphoma, 62, 1518-1521.
Shuai, P., Xu, H., Zhang, Y., Litvinov, Y. A., Wang, M., Tu, X., Blaum, K., Zhou, X., Yuan, Y., & Audi, G. (2014). arXiv. preprint arXiv:1407.3459.
Shylendra, S. P., Wajrak, M., Alameh, K., & Kang, J. J. (2023). Nafion modified titanium nitride pH sensor for future biomedical applications. Sensors, 23, 699.
Solomon, V. R., Alizadeh, E., Bernhard, W., Hartimath, S. V., Hill, W., Chekol, R., Barreto, K. M., Geyer, C. R., & Fonge, H. (2019). 111In- and225Ac-labeled cixutumumab for imaging and α-particle radiotherapy of IGF-1R positive triple-negative breast cancer. Molecular Pharmaceutics, 16, 4807-4816.
Soto-Perez-de-Celis, E., de Glas, N. A., Hsu, T., Kanesvaran, R., Steer, C., Navarrete-Reyes, A. P., Battisti, N. M. L., Chavarri-Guerra, Y., O'Donovan, A., & Avila-Funes, J. A. (2017). Global geriatric oncology: Achievements and challenges. Journal of Geriatric Oncology, 8, 374-386.
Strumińska-Parulska, D., & Falandysz, J. (2020). A review of the occurrence of alpha-emitting radionuclides in wild mushrooms. International Journal of Environmental Research and Public Health, 17, 8220.
Tafreshi, N., Kil, H. J., Pandya, D., Tichacek, C., Doligalski, M., Budzevich, M., Delva, N., Langsen, M., Moros, E., & Wadas, T. (2019). Lipophilicity Determines Route of Clearance of a Melanocortin 1 Receptor Targeted Radiopharmaceutical. Society of Nuclear Medicine, 60(1), 546.
Tafreshi, N. K., Pandya, D. N., Tichacek, C. J., Budzevich, M. M., Wang, Z., Reff, J. N., Engelman, R. W., Boulware, D. C., Chiappori, A. A., & Strosberg, J. R. (2021). Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. European Journal of Nuclear Medicine and Molecular Imaging, 48, 3408-3421.
Thiele, N. A., Brown, V., Kelly, J. M., Amor-Coarasa, A., Jermilova, U., MacMillan, S. N., Nikolopoulou, A., Ponnala, S., Ramogida, C. F., & Robertson, A. K. (2017). An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy. Angewandte Chemie International Edition, 56, 14712-14717.
Thiele, N. A., & Wilson, J. J. (2018). Actinium-225 for targeted α therapy: Coordination chemistry and current chelation approaches. Cancer Biotherapy & Radiopharmaceuticals, 33, 336-348.
Ulmert, D., Abou, D., Lilja, H., Larson, S., & Thorek, D. (2015). Targeted alpha-particle therapy of disseminated prostate cancer with 225-Actinium-11B6. Society of Nuclear Medicine, 56(3), 281.
Unak, P., Teksoz, S., Biber Muftuler, F., Medine, E., Acar, C., & Yurekli, Y. (2008). 99mTc-glucoheptonate-guanine: Synthesis, biodistribution and imaging in animals. Journal of Radioanalytical and Nuclear Chemistry, 275, 379-385.
Vallabhajosula, S. (2023). Radiopharmaceuticals for therapy. In Molecular imaging and targeted therapy: Radiopharmaceuticals and clinical applications (pp. 461-499). Springer.
Vasiliev, A., Zobnin, V., Pavlov, Y. S., & Chudakov, V. (2021). Radiation stability of sorbents in Medical225Ac/213Bi generators. Solvent Extraction and Ion Exchange, 39, 353-372.
Veach, D. R., Storey, C. M., Lückerath, K., Braun, K., Von Bodman, C., Lamminmäki, U., Kalidindi, T., Strand, S.-E., Strand, J., & Altai, M. (2021). PSA-targeted alpha-, Beta-, and positron-emitting Immunotheranostics in murine prostate cancer models and nonhuman primates. Clinical Cancer Research, 27, 2050-2060.
Vermeulen, K., Vandamme, M., Bormans, G., & Cleeren, F. (2019). Design and challenges of radiopharmaceuticals. Proceedings Seminars in Nuclear Medicine, 49(5), 339-356.
Woo, S., Kim, W., Lee, C., Lim, I., Song, K., & Lim, S. (2019). Cu-64/Ac-225-DOTA-rituximab internal dosimetry in mice using image-based Monte Carlo simulation. European Journal of Nuclear Medicine and Molecular Imaging, 46(1), S476-S476.
Yang, H., Wilson, J. J., Orvig, C., Li, Y., Wilbur, D. S., Ramogida, C. F., Radchenko, V., & Schaffer, P. (2022). Harnessingα-emitting radionuclides for therapy: Radiolabeling method review. Journal of Nuclear Medicine, 63, 5-13.
Yang, H., Zhang, C., Yuan, Z., Rodriguez-Rodriguez, C., Robertson, A., Radchenko, V., Perron, R., Gendron, D., Causey, P., & Gao, F. (2020). Synthesis and evaluation of a macrocyclic actinium-225 chelator, quality control and In vivo evaluation of225Ac-crown-αMSH peptide. Chemistry-A European Journal, 26, 11435-11440.
Yuan, R. R., Wong, P., McDevitt, M. R., Doubrovina, E., Leiner, I., Bornmann, W., O'reilly, R., Pamer, E. G., & Scheinberg, D. A. (2004). Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. Blood, 104, 2397-2402.
Zhang, J., Kulkarni, H. R., & Baum, R. P. (2020). Peptide receptor radionuclide therapy using 225Ac-DOTATOC achieves partial remission in a patient with progressive neuroendocrine liver metastases after repeated β-emitter peptide receptor radionuclide therapy. Clinical Nuclear Medicine, 45, 241-243.
Zhuikov, B., Kalmykov, S., Ermolaev, S., Aliev, R., Kokhanyuk, V., Matushko, V., Tananaev, I., & Myasoedov, B. (2011). Production of 225Ac and 223Ra by irradiation of Th with accelerated protons. Radiochemistry, 53, 73-80.